-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At the 2021 annual meeting of the American Endocrine Society (ENDO2021), the team of Professor Mila Sofie Welling, MD, Erasmus University University Medical Center in Rotterdam, published a study on the treatment of genetic obesity.
Liraglutide, a glycopeptide-1 (GLP-1) analogue, is related to the improvement of body weight, metabolic parameters and quality of life in patients with genetic obesity.
Previous studies on diabetes have shown that liraglutide, as an additional treatment, has a certain effect on improving blood sugar control in children and adolescents with type 2 diabetes (T2DM) .
To this end, liraglutide is FDA approved for the treatment of adult and aged over T2DM patients and T2DM used to reduce high blood pressure, stroke and medsci.
For this reason, liraglutide is approved by the FDA for the treatment of adults and T2DM patients over ten years of age, and used to reduce T2DM.
Weight rebound after weight loss is a major problem in the treatment of obese patients.
Weight rebound after weight loss is a major problem in the treatment of obese patients.
The endpoints of the study are the change in body weight (primary endpoint) and the change in body fat rate (secondary endpoint) of the intentionally treated population from randomization to the end of the treatment period.
After an 8-week low-calorie diet, the 195 participants lost an average of 13.
After 1 year, all active treatment strategies resulted in more weight loss than placebo: 4.
During the experiment, the weight changes of the four groups of participants over time
During the experiment, the weight changes of the four groups of participants over timeAt the same time, the secondary endpoint of the combination therapy group was also better, where the body fat rate was reduced by 3.
At the same time, the secondary endpoint of the combination therapy group was also better, where the body fat rate was reduced by 3.
Therefore, if you want to get an effective weight loss without rebound, combining exercise and liraglutide therapy may be a reliable choice.
references:
Lundgren JR,et al.
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
Leave a message here
